以多發靜脈血栓為首發表現的骨髓增生異常綜合征伴白塞病一例_West China Medical Journal

Authors：

代明輝 ^1,2 , 帥曉 ¹ ,  吳俁 ¹

1. ;
2. ;

Corresponding?author：

吳俁, Email: wu_yu@scu.edu.cn

Keywords：

骨髓增生異常綜合征; 白塞病; +8 染色體; 血栓; 潰瘍

DOI：

10.7507/1002-0179.202202027

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 代明輝, 帥曉, 吳俁. 以多發靜脈血栓為首發表現的骨髓增生異常綜合征伴白塞病一例. West China Medical Journal, 2023, 38(1): 147-150. doi: 10.7507/1002-0179.202202027 Copy

1.	中華醫學會血液學分會. 骨髓增生異常綜合征中國診斷與治療指南(2019 年版). 中華血液學雜志, 2019, 40(2): 89-97.
2.	Lee S. Diagnostic criteria of Beh?et’s disease: problems and suggestions. Yonsei Med J, 1997, 38(6): 365-369.
3.	Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood, 2012, 120(12): 2454-2465.
4.	Kristinsson SY, Bj?rkholm M, Hultcrantz M, et al. Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes. J Clin Oncol, 2011, 29(21): 2897-2903.
5.	Utley SM. Myelodysplastic syndromes. Semin Oncol Nurs, 1996, 12(1): 51-58.
6.	Ozguler Y, Hatemi G. Management of Beh?et’s syndrome. Curr Opin Rheumatol, 2016, 28(1): 45-50.
7.	Haga N, Iwata H, Yamaguchi Y, et al. Mucocutaneous pyoderma gangrenosum due to trisomy 8 neutrophilic infiltrates in a patient with myelodysplastic syndrome. Br J Dermatol, 2016, 174(1): 239-241.
8.	Komrokji RS, Kulasekararaj A, Al Ali NH, et al. Autoimmune diseases and myelodysplastic syndromes. Am J Hematol, 2016, 91(5): E280-E283.
9.	Seguier J, Gelsi-Boyer V, Ebbo M, et al. Autoimmune diseases in myelodysplastic syndrome favors patients survival: a case control study and literature review. Autoimmun Rev, 2019, 18(1): 36-42.
10.	Ivy KS, Brent Ferrell P. Disordered immune regulation and its therapeutic targeting in myelodysplastic syndromes. Curr Hematol Malig Rep, 2018, 13(4): 244-255.
11.	Kimura S, Kuroda J, Akaogi T, et al. Trisomy 8 involved in myelodysplastic syndromes as a risk factor for intestinal ulcers and thrombosis: Beh?et’s syndrome. Leuk Lymphoma, 2001, 42(1/2): 115-121.
12.	Chen G, Zeng W, Miyazato A, et al. Distinctive gene expression profiles of CD34 cells from patients with myelodysplastic syndrome characterized by specific chromosomal abnormalities. Blood, 2004, 104(13): 4210-4218.
13.	Cagnin S, Biscuola M, Patuzzo C, et al. Reconstruction and functional analysis of altered molecular pathways in human atherosclerotic arteries. BMC Genomics, 2009, 10: 13.
14.	Grainger DJ. Transforming growth factor beta and atherosclerosis: so far, so good for the protective cytokine hypothesis. Arterioscler Thromb Vasc Biol, 2004, 24(3): 399-404.
15.	歐陽, 吳俁. 骨髓增生異常綜合征免疫異常機制的研究新進展. 國際輸血及血液學雜志, 2021, 44(1): 22-28.
16.	Yazici H, Seyahi E, Hatemi G, et al. Beh?et syndrome: a contemporary view. Nat Rev Rheumatol, 2018, 14(2): 119.
17.	Hatemi G, Seyahi E, Fresko I, et al. One year in review 2020: Beh?et’s syndrome. Clin Exp Rheumatol, 2020, 38(5, Suppl 127): 3-10.
18.	Shen Y, Ma HF, Luo D, et al. High incidence of gastrointestinal ulceration and cytogenetic aberration of trisomy 8 as typical features of Beh?et’s disease associated with myelodysplastic syndrome: a series of 16 consecutive Chinese patients from the Shanghai Beh?et’s disease database and comparison with the literature. Biomed Res Int, 2018, 2018: 8535091.
19.	Handa T, Nakatsue T, Baba M, et al. Clinical features of three cases with pulmonary alveolar proteinosis secondary to myelodysplastic syndrome developed during the course of Beh?et’s disease. Respir Investig, 2014, 52(1): 75-79.
20.	Ahn JK, Cha HS, Koh EM, et al. Behcet’s disease associated with bone marrow failure in Korean patients: clinical characteristics and the association of intestinal ulceration and trisomy 8. Rheumatology (Oxford), 2008, 47(8): 1228-1230.
21.	Toyonaga T, Nakase H, Matsuura M, et al. Refractoriness of intestinal Beh?et’s disease with myelodysplastic syndrome involving trisomy 8 to medical therapies - our case experience and review of the literature. Digestion, 2013, 88(4): 217-221.
22.	Kawano S, Hiraoka S, Okada H, et al. Clinical features of intestinal Beh?et’s disease associated with myelodysplastic syndrome and trisomy 8. Acta Med Okayama, 2015, 69(6): 365-369.
23.	Hulscher JB, van den Berg HP, Siegert CE, et al. A Turkish man with Beh?et disease and recurrent acute abdomen. Ned Tijdschr Geneeskd, 2003, 147(40): 1969-1971.
24.	Tanaka H, Shimizu N, Tougasaki E, et al. Successful treatment by azacitidine therapy of intestinal Beh?et’s disease associated with myelodysplastic syndrome. Int J Hematol, 2013, 97(4): 520-524.
25.	Yilmaz U, Ar MC, Esatoglu SN, et al. How to treat myelodysplastic syndrome with clinical features resembling Beh?et syndrome: a case-based systematic review. Ann Hematol, 2020, 99(6): 1193-1203.
26.	Fenaux P, Platzbecker U, Mufti GJ, et al. Luspatercept in patients with lower-risk myelodysplastic syndromes. N Engl J Med, 2020, 382(2): 140-151.

1. 中華醫學會血液學分會. 骨髓增生異常綜合征中國診斷與治療指南(2019 年版). 中華血液學雜志, 2019, 40(2): 89-97.
2. Lee S. Diagnostic criteria of Beh?et’s disease: problems and suggestions. Yonsei Med J, 1997, 38(6): 365-369.
3. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood, 2012, 120(12): 2454-2465.
4. Kristinsson SY, Bj?rkholm M, Hultcrantz M, et al. Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes. J Clin Oncol, 2011, 29(21): 2897-2903.
5. Utley SM. Myelodysplastic syndromes. Semin Oncol Nurs, 1996, 12(1): 51-58.
6. Ozguler Y, Hatemi G. Management of Beh?et’s syndrome. Curr Opin Rheumatol, 2016, 28(1): 45-50.
7. Haga N, Iwata H, Yamaguchi Y, et al. Mucocutaneous pyoderma gangrenosum due to trisomy 8 neutrophilic infiltrates in a patient with myelodysplastic syndrome. Br J Dermatol, 2016, 174(1): 239-241.
8. Komrokji RS, Kulasekararaj A, Al Ali NH, et al. Autoimmune diseases and myelodysplastic syndromes. Am J Hematol, 2016, 91(5): E280-E283.
9. Seguier J, Gelsi-Boyer V, Ebbo M, et al. Autoimmune diseases in myelodysplastic syndrome favors patients survival: a case control study and literature review. Autoimmun Rev, 2019, 18(1): 36-42.
10. Ivy KS, Brent Ferrell P. Disordered immune regulation and its therapeutic targeting in myelodysplastic syndromes. Curr Hematol Malig Rep, 2018, 13(4): 244-255.
11. Kimura S, Kuroda J, Akaogi T, et al. Trisomy 8 involved in myelodysplastic syndromes as a risk factor for intestinal ulcers and thrombosis: Beh?et’s syndrome. Leuk Lymphoma, 2001, 42(1/2): 115-121.
12. Chen G, Zeng W, Miyazato A, et al. Distinctive gene expression profiles of CD34 cells from patients with myelodysplastic syndrome characterized by specific chromosomal abnormalities. Blood, 2004, 104(13): 4210-4218.
13. Cagnin S, Biscuola M, Patuzzo C, et al. Reconstruction and functional analysis of altered molecular pathways in human atherosclerotic arteries. BMC Genomics, 2009, 10: 13.
14. Grainger DJ. Transforming growth factor beta and atherosclerosis: so far, so good for the protective cytokine hypothesis. Arterioscler Thromb Vasc Biol, 2004, 24(3): 399-404.
15. 歐陽, 吳俁. 骨髓增生異常綜合征免疫異常機制的研究新進展. 國際輸血及血液學雜志, 2021, 44(1): 22-28.
16. Yazici H, Seyahi E, Hatemi G, et al. Beh?et syndrome: a contemporary view. Nat Rev Rheumatol, 2018, 14(2): 119.
17. Hatemi G, Seyahi E, Fresko I, et al. One year in review 2020: Beh?et’s syndrome. Clin Exp Rheumatol, 2020, 38(5, Suppl 127): 3-10.
18. Shen Y, Ma HF, Luo D, et al. High incidence of gastrointestinal ulceration and cytogenetic aberration of trisomy 8 as typical features of Beh?et’s disease associated with myelodysplastic syndrome: a series of 16 consecutive Chinese patients from the Shanghai Beh?et’s disease database and comparison with the literature. Biomed Res Int, 2018, 2018: 8535091.
19. Handa T, Nakatsue T, Baba M, et al. Clinical features of three cases with pulmonary alveolar proteinosis secondary to myelodysplastic syndrome developed during the course of Beh?et’s disease. Respir Investig, 2014, 52(1): 75-79.
20. Ahn JK, Cha HS, Koh EM, et al. Behcet’s disease associated with bone marrow failure in Korean patients: clinical characteristics and the association of intestinal ulceration and trisomy 8. Rheumatology (Oxford), 2008, 47(8): 1228-1230.
21. Toyonaga T, Nakase H, Matsuura M, et al. Refractoriness of intestinal Beh?et’s disease with myelodysplastic syndrome involving trisomy 8 to medical therapies - our case experience and review of the literature. Digestion, 2013, 88(4): 217-221.
22. Kawano S, Hiraoka S, Okada H, et al. Clinical features of intestinal Beh?et’s disease associated with myelodysplastic syndrome and trisomy 8. Acta Med Okayama, 2015, 69(6): 365-369.
23. Hulscher JB, van den Berg HP, Siegert CE, et al. A Turkish man with Beh?et disease and recurrent acute abdomen. Ned Tijdschr Geneeskd, 2003, 147(40): 1969-1971.
24. Tanaka H, Shimizu N, Tougasaki E, et al. Successful treatment by azacitidine therapy of intestinal Beh?et’s disease associated with myelodysplastic syndrome. Int J Hematol, 2013, 97(4): 520-524.
25. Yilmaz U, Ar MC, Esatoglu SN, et al. How to treat myelodysplastic syndrome with clinical features resembling Beh?et syndrome: a case-based systematic review. Ann Hematol, 2020, 99(6): 1193-1203.
26. Fenaux P, Platzbecker U, Mufti GJ, et al. Luspatercept in patients with lower-risk myelodysplastic syndromes. N Engl J Med, 2020, 382(2): 140-151.

Previous Article
Research progress on the treatment of limb motor dysfunction after stroke based on brain-limb coordinate regulation
Next Article
青年精神分裂癥患者顱內靜脈血栓形成一例

West China Medical Journal

以多發靜脈血栓為首發表現的骨髓增生異常綜合征伴白塞病一例

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content